CAJ | 학술논문

目的：观察氟哌噻吨美利曲辛在治疗胃食管反流性咳嗽(GERC)中的作用。方法收集2012年10月—2013年11月确诊 GERC 者73例,将其中焦虑、抑郁患者分为 A、B 组,无焦虑抑郁患者,定为 C 组,A 组28例,B组24例,C 组21例。 B 组、C 组患者进行常规抗反流治疗,A 组加用氟哌噻吨美利曲辛片治疗。治疗12周后评估患者 GERD-Q 量表及咳嗽症状积分变化。结果3组治疗第4、8、12周后 GERD-Q 积分、咳嗽症状积分较治疗前均有所下降(P <0．01,P <0．05)；治疗第4、8、12周后 GERD-Q 量表评分、咳嗽症状积分降低程度 A、C 组均高于 B 组(P <0．01,P <0．05),A、C 组间无统计学差异(P >0．05)；A、C 组总有效率明显高于 B 组(P <0．05),A、C 组间无统计学差异(P >0．05)。结论埃索美拉唑、莫沙必利联合氟哌噻吨美利曲辛片治疗伴有焦虑、抑郁状态 GERC 患者,具有价格低廉、疗效确切、服用方便、不良反应少等优点。
목적：관찰불고새둔미리곡신재치료위식관반류성해수(GERC)중적작용。방법수집2012년10월—2013년11월학진 GERC 자73례,장기중초필、억욱환자분위 A、B 조,무초필억욱환자,정위 C 조,A 조28례,B조24례,C 조21례。 B 조、C 조환자진행상규항반류치료,A 조가용불고새둔미리곡신편치료。치료12주후평고환자 GERD-Q 량표급해수증상적분변화。결과3조치료제4、8、12주후 GERD-Q 적분、해수증상적분교치료전균유소하강(P <0．01,P <0．05)；치료제4、8、12주후 GERD-Q 량표평분、해수증상적분강저정도 A、C 조균고우 B 조(P <0．01,P <0．05),A、C 조간무통계학차이(P >0．05)；A、C 조총유효솔명현고우 B 조(P <0．05),A、C 조간무통계학차이(P >0．05)。결론애색미랍서、막사필리연합불고새둔미리곡신편치료반유초필、억욱상태 GERC 환자,구유개격저렴、료효학절、복용방편、불량반응소등우점。
Objective To observe the effect of Flupentixol and Melitracen Tablets in treatment of patients with gastroesophageal reflux cough (GERC). Methods A total of 73 GERC patients admitted during October 2012 and No-vember 2013 were recruited in this study. Patients with depression and anxiety were divided into group A (n = 28) and group B (n = 24), while patients without depression and anxiety were recruited as group C (n = 21). Group A, B and C were treated with conventional anti-reflux therapy, while group A was added with Flupentixol and Melitracen Tablets. The changes of gastroesophageal reflux disease questionnaire (GERD-Q) scale and cough symptom score were assessed after 12 week of treatment. Results The values of GERD-Q scale and cough symptom score in the 4th , 8th and 12th week of treatment were significantly lower than those before the treatment in the 3 groups (P < 0. 01, P < 0. 05); the decreased values in the 4th , 8th and 12th week of treatment in group A and C were more significant compared with those in group B (P < 0. 01, P < 0. 05), while the differences in the values between group A and C were not statistically significant (P >0. 05). The total effective rates of group A and C were significantly higher than that of group B (P < 0. 05), while there was no statistically significant difference in the rates between group A and C (P > 0. 05). Conclusion Esomeprazole and Mosapride combined with Flupentixol and Melitracen Tables in treatment of GERC patients with anxiety and depres-sion may quickly improve the symptoms with cheaper cost, easier application and fewer adverse reaction.